Clinical Trial Update: Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial) [Phase 3]

View source ↗

Summary

The OraGO-1 trial is a Phase 3 study comparing one-week versus two-week orbital radiotherapy for Graves' ophthalmopathy and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy

Snippet

Sponsor: Janjira Petsuksiri | Conditions: Thyroid Associated Ophthalmopathy | Phase 3 | Status: RECRUITING